Asia-Pacific Adenomyosis Drugs Market, By Type (Diffuse, Nodular, Sclerotic, Adult Cystic, and Others), Treatment (Hormone Medication, Anti-Inflammatory Drugs, and Others), Patient Type (Adult, Geriatric, and Adolescence), Dosage Form (Parenteral, Oral, Others), End-User (Hospitals, Clinics, Specialty Center, Home Healthcare, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2030.
Asia-Pacific Adenomyosis Drugs Market Analysis and Size
Adenomyosis is a benign uterine disorder in which endometrial glands and stroma are pathologically demonstrated in the myometrium. Women affected by adenomyosis may present with abnormal uterine bleeding (AUB), dysmenorrhea, dyspareunia, or infertility, but one-third of them are asymptomatic. Over the years, adenomyosis has remained a histopathological diagnosis made after hysterectomy in perimenopausal women with heavy menstrual bleeding (HMB) or pelvic pain. However, adenomyosis has also become a condition identified in young fertile-age women over the last decade because of the recent advancements in imaging techniques, even though a shared definition and classification are still lacking. Despite the improvement of diagnostic tools, the awareness of the condition is still poor.
Data Bridge Market Research analyses that the Asia-Pacific adenomyosis drugs market which was USD 2.37 million in 2022, is expected to reach USD 3.95 million by 2030, and is likely to undergo a CAGR of 6.6% during the forecast period of 2023 to 2030. “Anti-inflmmatory drugs” dominates the treatment segment of the adenomyosis drugs market as drugs used for the treatment of adenomyosis generally include anti-inflammatory drugs. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asia-Pacific Adenomyosis Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Diffuse, Nodular, Sclerotic, Adult Cystic, and Others), Treatment (Hormone Medication, Anti-Inflammatory Drugs, and Others), Patient Type (Adult, Geriatric, and Adolescence), Dosage Form (Parenteral, Oral, Others), End-User (Hospitals, Clinics, Specialty Center, Home Healthcare, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)
|
|
Countries Covered
|
Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of the Asia-Pacific
|
|
Market Players Covered
|
Mayne Pharma Group Limited (Australia), Accord Healthcare (U.K.), Boehringer Ingelheim International GmbH (Germany), Ferring B.V. (Switzerland), Par Pharmaceutical (A Subsidiary of Endo International plc) (U.S.), Hikma Pharmaceuticals PLC (U.K.), Viatris Inc. (U.S.), Bayer AG (Germany), Teva Pharmaceutical Industries Ltd.(Israel), AstraZeneca (U.K.), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd (India), AbbVie Inc. (U.S.), Abbott(U.S.), GlaxoSmithKline plc. (U.K.), Novartis AG (Switzerland), Amneal Pharmaceuticals LLC(U.S.), Johnson & Johnson Services, Inc. (U.S.), Sanofi (France), Dr. Reddy's Laboratories Ltd. (India) among others
|
|
Market Opportunities
|
|
Market Definition
Adenomyosis represents a unique pathophysiological condition in which normal-appearing endometrial mucosa resides within the myometrium and is thus protected from menstrual shedding. The resulting ectopic presence of endometrial tissue composed of glands and stroma is thought to affect normal contractile function and peristalsis of uterine smooth muscle, causing menometrorrhagia, infertility, and adverse obstetric outcomes. Adenomyosis imposes a substantial socioeconomic burden from increased medical care and loss of work productivity without mentioning the compromised quality of life.
Global Adenomyosis Drugs Market Dynamics
Drivers
- Increasing Prevalence of Adenomyosis
The rising incidence and prevalence of adenomyosis in the Asia-Pacific region is a significant driver for the market. Adenomyosis is a common gynecological disorder among women, and as awareness grows and diagnostic capabilities improve, more cases are being identified and treated. This drives the demand for adenomyosis drugs.
- Advancements in Medical Technology
Advances in medical technology, including improved diagnostic methods and minimally invasive surgical techniques, are leading to earlier and more accurate diagnoses of adenomyosis. This, in turn, is driving the demand for drugs that can effectively manage the condition, as patients and healthcare providers seek less invasive treatment options.
- Aging Population
The aging population in the Asia-Pacific region is contributing to the growth of adenomyosis cases. Older women are at a higher risk of developing adenomyosis, and as the population ages, the demand for drugs to manage the condition is likely to increase.
- Growing Investment for Healthcare Facilities
Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
Opportunities
- Advancements in Research and Development
Ongoing research in the field of gynecology and women's health is leading to the development of new and more effective drugs for adenomyosis. Pharmaceutical companies can capitalize on these advancements by introducing innovative treatment options that provide better outcomes and fewer side effects, which can differentiate their products in the market.
- Telemedicine and Digital Health Solutions
The adoption of telemedicine and digital health solutions in the Asia-Pacific region is on the rise, especially in the wake of the COVID-19 pandemic. This presents an opportunity for healthcare providers and pharmaceutical companies to reach and educate patients about adenomyosis treatments remotely, improving access to healthcare services and medications.
Restraints/Challenges
- Limited Awareness and Diagnosis
Adenomyosis is often underdiagnosed or misdiagnosed as other gynecological conditions, leading to delayed or incorrect treatment. Limited awareness among both patients and healthcare providers can hinder the market's growth, as early diagnosis and treatment are crucial for effective management.
- High Treatment Costs
The cost of adenomyosis drugs and treatments can be a significant barrier, especially in countries with lower healthcare budgets and a large proportion of out-of-pocket healthcare expenses. High treatment costs may limit access to effective therapies for many patients.
- Underdiagnosis and Misdiagnosis
Adenomyosis is often underdiagnosed or misdiagnosed as other gynecological conditions, such as endometriosis or fibroids. Accurate diagnosis can be challenging, and this delay or misdiagnosis can hinder the timely initiation of appropriate treatment. Addressing this challenge requires increased awareness and improved diagnostic methods.
- Limited Treatment Options
Currently, there are limited specific drugs approved for the treatment of adenomyosis. Most treatment approaches involve managing symptoms, such as pain and heavy menstrual bleeding, rather than directly targeting the underlying condition. The lack of dedicated medications for adenomyosis can be a significant challenge for patients and healthcare providers seeking effective treatments.
This adenomyosis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the adenomyosis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In October 2021, Debiopharm, a Swiss-based, Asia-Pacific biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, announced the Indonesian launch of triptorelin for the treatment of women with gynecological disorders, particularly adenomyosis, and its related diseases
- In September 2019, Professor Caroline Gargett and collaborators at the University of Queensland and Monash IVF were awarded a three-year USD 2.07 million (AUD 3.05 million) grant to determine the cause of adenomyosis and the physiological processes associated with the diseases
Asia-Pacific Adenomyosis Drugs Market Scope
The adenomyosis drugs market is segmented on the basis of type, treatment, patient type, dosage form, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Diffuse
- Nodular
- Sclerotic
- Adult Cystic
- Others
Treatment
- Hormone Medications
- Anti-inflammatory Drugs
- Others
Patient Type
- Adolescence
- Adult
- Geriatric
Dosage Form
- Parenteral
- Oral
- Others
End-User
- Hospitals
- Clinics
- Specialty Center
- Home Healthcare
- Ambulatory Centers
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Asia-Pacific Adenomyosis Drugs Market Regional Analysis/Insights
The adenomyosis drugs market is analysed and market size insights and trends are provided by type, treatment, patient type, dosage form, distribution channel and end-user as referenced above.
The countries covered in the adenomyosis drugs market report are Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, and Rest of the Asia-Pacific.
Japan is expected to dominate the Asia-Pacific market during the forecast period due to the increased incidence and diagnosis of the disease.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Adenomyosis Drugs Market Share Analysis
The adenomyosis drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company's focus related to adenomyosis drugs market.
Some of the major players operating in the adenomyosis drugs market are:
- Mayne Pharma Group Limited (Australia)
- Accord Healthcare (U.K.)
- Boehringer Ingelheim International GmbH (Germany)
- Ferring B.V. (Switzerland)
- Par Pharmaceutical (A Subsidiary of Endo International plc) (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Viatris Inc. (U.S.)
- Bayer AG (Germany)
- Teva Pharmaceutical Industries Ltd. (Israel)
- AstraZeneca (U.K.)
- Pfizer Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd (India)
- AbbVie Inc. (U.S.)
- Abbott (U.S.)
- GlaxoSmithKline plc. (U.K.)
- Novartis AG (Switzerland)
- Amneal Pharmaceuticals LLC (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- Sanofi (France)
- Dr. Reddy's Laboratories Ltd. (India)
SKU-